HER2阳性浸润性乳腺癌新辅助治疗反应的预测因子及治疗前后HER2状态变化的评估

刘建兰; 陈黛诗; 胡泓; 周冬仙; 胡锦涛

doi:10.19401/j.cnki.1007-3639.2022.05.007

您当前的位置：

首页 >

文章列表页 >

HER2阳性浸润性乳腺癌新辅助治疗反应的预测因子及治疗前后HER2状态变化的评估

论著 | 更新时间：2025-12-31

- HER2阳性浸润性乳腺癌新辅助治疗反应的预测因子及治疗前后HER2状态变化的评估
- Predictors of response to neoadjuvant treatment and changes to HER2 status in HER2-positive invasive breast cancer
- 中国癌症杂志 2022年32卷第5期页码：417-426
- 作者机构：
  
  1. 深圳市人民医院（暨南大学第二临床医学院,南方科技大学第一附属医院）病理科,广东深圳 518020
  2. 深圳市人民医院（暨南大学第二临床医学院,南方科技大学第一附属医院）耳鼻咽喉科,广东深圳 518020
  3. 深圳市人民医院（暨南大学第二临床医学院,南方科技大学第一附属医院）甲乳外科,广东深圳 518020
- 作者简介：
  
  [ "刘建兰（ORCID: 0000-0001-6910-5829）,硕士,主治医师 E-mail: liujianlan2013@163.com" ]
  胡锦涛（ORCID: 0000-0003-3577-6944）,硕士,副主任医师 E-mail: huqiuhan@126.com
- 基金信息：
  
  深圳市自然科学基金(JCYJ20190807145415068);国家自然科学基金(31801160)
- DOI：10.19401/j.cnki.1007-3639.2022.05.007
  中图分类号： R737.9
- 收稿：2021-11-01，
  
  修回：2022-02-20，
  
  纸质出版：2022-05-30
- 稿件说明：
移动端阅览
刘建兰, 陈黛诗, 胡泓, 等. HER2阳性浸润性乳腺癌新辅助治疗反应的预测因子及治疗前后HER2状态变化的评估[J]. 中国癌症杂志, 2022,32(5):417-426.

Jianlan LIU, Daishi CHEN, Hong HU, et al. Predictors of response to neoadjuvant treatment and changes to HER2 status in HER2-positive invasive breast cancer[J]. China Oncology, 2022, 32(5): 417-426.
刘建兰, 陈黛诗, 胡泓, 等. HER2阳性浸润性乳腺癌新辅助治疗反应的预测因子及治疗前后HER2状态变化的评估[J]. 中国癌症杂志, 2022,32(5):417-426. DOI： 10.19401/j.cnki.1007-3639.2022.05.007.

Jianlan LIU, Daishi CHEN, Hong HU, et al. Predictors of response to neoadjuvant treatment and changes to HER2 status in HER2-positive invasive breast cancer[J]. China Oncology, 2022, 32(5): 417-426. DOI： 10.19401/j.cnki.1007-3639.2022.05.007.

摘要

背景与目的：

人表皮生长因子受体2（human epidermal growth factor receptor 2

HER2）阳性浸润性乳腺癌对抗于HER2新辅助治疗的反应显著

然而不同患者的反应并不一致

部分反应较差。本研究旨在探讨HER2阳性乳腺癌新辅助治疗反应的预测因子

并进一步评估新辅助治疗前后HER2状态的不一致性。

方法：

收集深圳市人民医院2019

#x02014;2021年经术前粗针穿刺活检确诊的110例HER2阳性乳腺癌患者

经新辅助治疗后行手术切除。采用免疫组织化学（immunohistochemistry

IHC）及荧光原位杂交（fluorescence

in situ

hybridization

FISH）检测术前穿刺标本中的HER2表达状态

并评估新辅助治疗后手术切除标本的病理学完全缓解（pathological complete response

pCR）状态及残余肿瘤负荷（residual cancer burden

RCB）分级

评价不同HER2状态对新辅助治疗效果的影响

并进一步比较新辅助治疗前后HER2、雌激素受体（estrogen receptor

ER）及孕激素受体（progesterone receptor

PR）状态的一致性。

结果

：110例乳腺癌患者根据HER2 IHC表达状态分为弥漫3+组（81例）、异质性3+组（20例）和2+且FISH基因扩增（2+FISH+）组（9例）。HER2弥漫3+组pCR率为54.3%

明显高于异质性3+组（5.0%）和2+FISH+组（11.1%）

差异有统计学意义（

0.05）

而异质性3+组和2+FISH+组的RCB分级更高。多因素分析显示

HER2弥漫3+是pCR的独立预测因子。7例（11.9%）HER2阳性乳腺癌患者在新辅助治疗后HER2转为阴性

大多数（85.7%）为异质性3+组和2+FISH+组病例。

结论：

HER2异质性会影响HER2阳性乳

腺癌的新辅助治疗反应

评价穿刺活检标本中HER2 IHC异质性

并对新辅助治疗后残留癌灶HER2、ER和PR状态重新评估

有利于指导下一步治疗。新型抗体药物偶联物（antibody-drug conjugate

ADC）的出现有望为HER2异质性阳性乳腺癌患者带来生存获益。

Abstract

Background and purpose:

The response of human epidermal growth factor receptor 2 (HER2)-positive invasive breast cancer to HER2 targeted neoadjuvant therapy is significant. However

the response is not uniform

and a proportion of patients respond poorly. This study aimed to identify predictors of response in the neoadjuvant treatment and to assess the discordance rate of HER2 status between pre- and post-treatment specimens in HER2-positive breast cancer.

Methods:

The study group included 110 HER2-positive breast cancer patients treated with neoadjuvant therapy and surgery who were diagnosed from 2019 to 2021 in Shenzhen People

#x02019;s Hospital. Immunohistochemistry (IHC) and fluorescence

in situ

hybridization (FISH) were used to detect the expression of HER2 in core needle biopsy specimens. Pathological complete response (pCR) and residual cancer burden (RCB) of surgically resected specimens after neoadjuvant therapy were used to assess the therapy response of patients. HER2

estrogen receptor (ER) and progesterone receptor (PR) status were further assessed in the residual invasive carcinoma present after neoadjuvant therapy.

Results:

One hundred and ten breast cancer patients were divided into IHC diffuse 3+ group (

=81)

heterogeneous 3+ group (

=20)

IHC 2+ and FISH amplified (2+FISH+) group (

=9). The pCR rate of HER2 diffuse 3+ group was 54.3%

which was significantly higher compared with heterogeneous 3+ group (5.0%) and 2+FISH+ group (11.1%)

and the difference was statistically significant (

0.05). RCB categories were higher in heterogeneous 3+ and 2+FISH+ groups. Multivariate analysis showed that HER2 diffuse 3+ was an independent predictor of pCR.

Seven cases (11.9%) became HER2-negative

the majority (85.7%) from heterogeneous 3+ and 2+FISH+ groups.

Conclusion:

HER2 heterogeneity predicts the neoadjuvant therapy response of HER2-positive breast cancer. Evaluation of the heterogeneity of HER2 IHC in biopsy specimens and repeating HER2

ER and PR testing after neoadjuvant treatment should therefore be considered

which will facilitate further management decisions. The patients with HER2 heterogeneity may potentially benefit from the novel antibody-drug conjugate (ADC).

关键词

Keywords

references

LOIBL S , GIANNI L . HER2-positive breast cancer [J ] . Lancet , 2017 , 389 ( 10087 ): 2415 - 2429 . DOI: 10.1016/S0140-6736(16)32417-5 http://doi.org/10.1016/S0140-6736(16)32417-5 https://linkinghub.elsevier.com/retrieve/pii/S0140673616324175 https://linkinghub.elsevier.com/retrieve/pii/S0140673616324175

HAYES D F . HER2 and breast cancer-a phenomenal success story [J ] . N Engl J Med , 2019 , 381 ( 13 ): 1284 - 1286 . DOI: 10.1056/NEJMcibr1909386 http://doi.org/10.1056/NEJMcibr1909386 http://www.nejm.org/doi/10.1056/NEJMcibr1909386 http://www.nejm.org/doi/10.1056/NEJMcibr1909386

VON MINCKWITZ G , HUANG C S , MANO M S , et al . Trastuzumab emtansine for residual invasive HER2-positive breast cancer [J ] . N Engl J Med , 2019 , 380 ( 7 ): 617 - 628 . DOI: 10.1056/NEJMoa1814017 http://doi.org/10.1056/NEJMoa1814017 http://www.nejm.org/doi/10.1056/NEJMoa1814017 http://www.nejm.org/doi/10.1056/NEJMoa1814017

BROGLIO K R , QUINTANA M , FOSTER M , et al . Association of pathologic complete response to neoadjuvant therapy in HER2-positive breast cancer with long-term outcomes: a meta-analysis [J ] . JAMA Oncol , 2016 , 2 ( 6 ): 751 - 760 . DOI: 10.1001/jamaoncol.2015.6113 http://doi.org/10.1001/jamaoncol.2015.6113 http://oncology.jamanetwork.com/article.aspx?doi=10.1001/jamaoncol.2015.6113 http://oncology.jamanetwork.com/article.aspx?doi=10.1001/jamaoncol.2015.6113

GIANNI L , EIERMANN W , SEMIGLAZOV V , et al . Neoadjuvant and adjuvant trastuzumab in patients with HER2-positive locally advanced breast cancer (NOAH): follow-up of a randomised controlled superiority trial with a parallel HER2-negative cohort [J ] . Lancet Oncol , 2014 , 15 ( 6 ): 640 - 647 . DOI: 10.1016/S1470-2045(14)70080-4 http://doi.org/10.1016/S1470-2045(14)70080-4 https://linkinghub.elsevier.com/retrieve/pii/S1470204514700804 https://linkinghub.elsevier.com/retrieve/pii/S1470204514700804

杨文涛 , 步宏 . 乳腺癌雌、孕激素受体免疫组织化学检测指南 [J ] . 中华病理学杂志 , 2015 , 44 ( 4 ): 237 - 239 .

YANG W T , BU H . Guidelines for immunohistochemical detection of estrogen and progesterone receptors in breast cancer [J ] . Chin J Pathol , 2015 , 44 ( 4 ): 237 - 239 .

杨文涛 , 步宏 . 乳腺癌HER2检测指南(2019版) [J ] . 中华病理学杂志 , 2019 , 48 ( 3 ): 169 - 175 .

YANG W T , BU H . Guideline for HER2 detection in breast cancer, the 2019 version [J ] . Chin J Pathol , 2019 , 48 ( 3 ): 169 - 175 .

SYMMANS W F , PEINTINGER F , HATZIS C , et al . Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy [J ] . J Clin Oncol , 2007 , 25 ( 28 ): 4414 - 4422 . DOI: 10.1200/JCO.2007.10.6823 http://doi.org/10.1200/JCO.2007.10.6823 https://ascopubs.org/doi/10.1200/JCO.2007.10.6823 https://ascopubs.org/doi/10.1200/JCO.2007.10.6823

KRYSTEL-WHITTEMORE M , XU J , BROGI E , et al . Pathologic complete response rate according to HER2 detection methods in HER2-positive breast cancer treated with neoadjuvant systemic therapy [J ] . Breast Cancer Res Treat , 2019 , 177 ( 1 ): 61 - 66 . DOI: 10.1007/s10549-019-05295-9 http://doi.org/10.1007/s10549-019-05295-9 https://doi.org/10.1007/s10549-019-05295-9 https://doi.org/10.1007/s10549-019-05295-9

SCHNEEWEISS A , CHIA S , HICKISH T , et al . Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase Ⅱ cardiac safety study (TRYPHAENA) [J ] . Ann Oncol , 2013 , 24 ( 9 ): 2278 - 2284 . DOI: 10.1093/annonc/mdt182 http://doi.org/10.1093/annonc/mdt182 https://linkinghub.elsevier.com/retrieve/pii/S0923753419369297 https://linkinghub.elsevier.com/retrieve/pii/S0923753419369297

GIANNI L , PIENKOWSKI T , IM Y H , et al . Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial [J ] . Lancet Oncol , 2012 , 13 ( 1 ): 25 - 32 . DOI: 10.1016/S1470-2045(11)70336-9 http://doi.org/10.1016/S1470-2045(11)70336-9 https://linkinghub.elsevier.com/retrieve/pii/S1470204511703369 https://linkinghub.elsevier.com/retrieve/pii/S1470204511703369

WANG Y H , SINGH K , DIZON D , et al . Immunohistochemical HER2 score correlates with response to neoadjuvant chemotherapy in HER2-positive primary breast cancer [J ] . Breast Cancer Res Treat , 2021 , 186 ( 3 ): 667 - 676 . DOI: 10.1007/s10549-021-06124-8 http://doi.org/10.1007/s10549-021-06124-8 https://doi.org/10.1007/s10549-021-06124-8 https://doi.org/10.1007/s10549-021-06124-8

RAKHA E A , MILIGY I M , QUINN C M , et al . Retrospective observational study of HER2 immunohistochemistry in borderline breast cancer patients undergoing neoadjuvant therapy, with an emphasis on Group 2 (HER2/CEP17 ratio ≥2.0, HER2 copy number [J ] . Br J Cancer , 2021 , 124 ( 11 ): 1836 - 1842 . DOI: 10.1038/s41416-021-01351-8 http://doi.org/10.1038/s41416-021-01351-8 https://doi.org/10.1038/s41416-021-01351-8 https://doi.org/10.1038/s41416-021-01351-8

FILHO O M , VIALE G , STEIN S , et al . Impact of HER2 heterogeneity on treatment response of early-stage HER2-positive breast cancer: phase Ⅱ neoadjuvant clinical trial of T-DM1 combined with pertuzumab [J ] . Cancer Discov , 2021 , 11 ( 10 ): 2474 - 2487 . DOI: 10.1158/2159-8290.CD-20-1557 http://doi.org/10.1158/2159-8290.CD-20-1557 https://aacrjournals.org/cancerdiscovery/article/11/10/2474/665567/Impact-of-HER2-Heterogeneity-on-Treatment-Response https://aacrjournals.org/cancerdiscovery/article/11/10/2474/665567/Impact-of-HER2-Heterogeneity-on-Treatment-Response

HARBECK N . Insights into biology of luminal HER2 vs enriched HER2 subtypes: therapeutic implications [J ] . Breast , 2015 , 24 ( Suppl 2 ): S44 - S48 .

KATAYAMA A , MILIGY I M , SHIINO S , et al . Predictors of pathological complete response to neoadjuvant treatment and changes to post-neoadjuvant HER2 status in HER2-positive invasive breast cancer [J ] . Mod Pathol , 2021 , 34 ( 7 ): 1271 - 1281 . DOI: 10.1038/s41379-021-00738-5 http://doi.org/10.1038/s41379-021-00738-5 https://doi.org/10.1038/s41379-021-00738-5 https://doi.org/10.1038/s41379-021-00738-5

GIULIANI S , CINISELLI C M , LEONARDI E , et al . In a cohort of breast cancer screened patients the proportion of HER2 positive cases is lower than that earlier reported and pathological characteristics differ between HER2 3+ and HER2 2+/HER2 amplified cases [J ] . Virchows Arch , 2016 , 469 ( 1 ): 45 - 50 . DOI: 10.1007/s00428-016-1940-y http://doi.org/10.1007/s00428-016-1940-y http://link.springer.com/10.1007/s00428-016-1940-y http://link.springer.com/10.1007/s00428-016-1940-y

CORTAZAR P , ZHANG L J , UNTCH M , et al . Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis [J ] . Lancet , 2014 , 384 ( 9938 ): 164 - 172 . DOI: 10.1016/S0140-6736(13)62422-8 http://doi.org/10.1016/S0140-6736(13)62422-8 https://linkinghub.elsevier.com/retrieve/pii/S0140673613624228 https://linkinghub.elsevier.com/retrieve/pii/S0140673613624228

TANIOKA M , SASAKI M , SHIMOMURA A , et al . Pathologic complete response after neoadjuvant chemotherapy in HER2-overexpressing breast cancer according to hormonal receptor status [J ] . Breast , 2014 , 23 ( 4 ): 466 - 472 . DOI: 10.1016/j.breast.2014.03.008 http://doi.org/10.1016/j.breast.2014.03.008 https://linkinghub.elsevier.com/retrieve/pii/S0960977614000526 https://linkinghub.elsevier.com/retrieve/pii/S0960977614000526

BRANCO F P , MACHADO D , SILVA F F , et al . Loss of HER2 and disease prognosis after neoadjuvant treatment of HER2+ breast cancer [J ] . Am J Transl Res , 2019 , 11 ( 9 ): 6110 - 6116 .

GUARNERI V , DIECI M V , BARBIERI E , et al . Loss of HER2 positivity and prognosis after neoadjuvant therapy in HER2-positive breast cancer patients [J ] . Ann Oncol , 2013 , 24 ( 12 ): 2990 - 2994 . DOI: 10.1093/annonc/mdt364 http://doi.org/10.1093/annonc/mdt364 https://linkinghub.elsevier.com/retrieve/pii/S0923753419367249 https://linkinghub.elsevier.com/retrieve/pii/S0923753419367249

LILLEMOE T J , RENDI M , TSAI M L , et al . HER2 testing characteristics can predict residual cancer burden following neoadjuvant chemotherapy in HER2-positive breast cancer [J ] . Int J Breast Cancer , 2021 , 2021 : 6684629 .

朱逸晖 , 李婷 , 胡夕春 . Trastuzumab deruxtecan的临床研究进展及展望: HER2耐药患者的新希望 [J ] . 中国癌症杂志 , 2021 , 31 ( 8 ): 754 - 761 .

ZHU Y H , LI T , HU X C . Clinical research progress and prospect of trastuzumab deruxtecan [J ] . China Oncol , 2021 , 31 ( 8 ): 754 - 761 .

浏览量

3267

下载量

CSCD

文章被引用时，请邮件提醒。

提交

工具集

关联资源

乳腺癌新辅助治疗后的腋窝管理及前哨淋巴结诊治的优化

MRI预测乳腺癌淋巴结状态的研究进展及展望

早期乳腺癌局部治疗与全身治疗的进展与展望

乳腺癌新辅助治疗后腋窝淋巴结转移情况分析

血浆长链非编码RNA H19对乳腺癌新辅助治疗效果的预测价值